| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.62▼ | 3.56▼ | 3.57▼ | 3.55▲ | 3.54▲ |
| MA10 | 3.60▼ | 3.55▲ | 3.55▲ | 3.53▲ | 3.59▼ |
| MA20 | 3.55▼ | 3.51▲ | 3.51▲ | 3.59▼ | 3.35▲ |
| MA50 | 3.70▼ | 3.74▼ | 3.74▼ | 3.53▲ | 4.60▼ |
| MA100 | 3.71▼ | 3.51▲ | 3.51▲ | 3.32▲ | N/A |
| MA200 | 3.45▲ | 3.31▲ | 3.33▲ | 4.08▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.011▲ | 0.012▲ | 0.010▲ | -0.011▼ | 0.143▲ |
| RSI | 48.127▼ | 48.654▼ | 47.887▼ | 49.365▼ | 47.565▼ |
| STOCH | 66.074 | 54.977 | 57.347 | 51.481 | 61.023 |
| WILL %R | -55.556 | -55.556 | -47.059 | -35.938 | -43.103 |
| CCI | -28.868 | -27.758 | -9.524 | 108.632▲ | 40.979 |
|
Tuesday, September 29, 2026 07:07 AM
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative ...
|
|
Tuesday, September 29, 2026 05:00 AM
Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ltd. (NYSE: NSRX) (“” or the “Company”), a clinical-stage pharmaceutical ...
|
|
Tuesday, September 22, 2026 11:24 PM
Detailed price information for Nasus Pharma Ltd (NSRX-A) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 29/09/26 | 3.76 | 3.79 | 3.5382 | 3.57 | 32,182 |
| 28/09/26 | 3.69 | 3.78 | 3.35 | 3.59 | 114,762 |
| 25/09/26 | 3.4999 | 3.595 | 3.425 | 3.48 | 20,955 |
| 24/09/26 | 3.35 | 3.50 | 3.35 | 3.48 | 3,940 |
| 23/09/26 | 3.57 | 3.79 | 3.50 | 3.64 | 14,914 |
| 22/09/26 | 3.48 | 3.68 | 3.45 | 3.57 | 12,454 |
| 21/09/26 | 3.46 | 3.53 | 3.35 | 3.44 | 5,928 |
| 18/09/26 | 3.35 | 3.58 | 3.35 | 3.53 | 12,020 |
| 17/09/26 | 3.535 | 3.5857 | 3.46 | 3.53 | 7,639 |
| 16/09/26 | 3.64 | 3.72 | 3.41 | 3.46 | 10,949 |
|
|
||||
|
|
||||
|
|